You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. NOVEL MINIMALLY INVASIVE METHOD TO IDENTIFY LUNG MALIGNANCIES BY MRI

    SBC: 3TP IMAGING SCIENCES            Topic: N/A

    DESCRIPTION (provided by applicant): Project Summary. The overall goal of this research program is to develop a novel magnetic resonance (MR) image analysis method that can distinguish between malignant and benign lung nodules in patients who are undergoing diagnostic evaluation for lung cancer. 3TP Imaging Sciences has developed MR image analysis software that can be used to characterize the stat ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  2. Enhancing the immunogenicity of idiotypes for therapy of Non-Hodgkin's lymphoma

    SBC: ADVAXIS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Non-Hodgkin's Lymphoma (NHL) is characterized by an indolent clinical course with a median survival of 6- 10 years. The incidence of NHL in the US increases by about 2.5% per year. Clearly, there is a national need for improved therapies for this malignancy. Idiotype-based clinical trials for minimal residual disease of follicular NHL have shown increased disea ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  3. Anti-Fibrotic Therapy for Pulmonary Fibrosis

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Pulmonary Fibrosis is a diffuse interstitial lung disease characterized by chronic inflammation and progressive fibrosis of unknown etiology. Pulmonary fibrosis affects five million people worldwide and in the United States there are over 200,000 patients with pulmonary fibrosis. Of these more than 40,000 expire annually. Typically, patients are in their fortie ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  4. Small Molecule Therapeutics for Myocardial Ischemia

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Left untreated, myocardial ischemia can lead to cardiomyocyte death and pump failure. In fact, myocardial infarction is a significant cause of morbidity and mortality in the U.S. Recent evidence suggests that scatter factor / hepatocyte growth factor, exerts direct protective effects on cardiac myocytes and can potentially be used for salvage of the ischemic my ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Small Molecule Therapeutic for Spinal Cord Injury

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): It is estimated that the annual incidence of spinal cord injury (SCI), not including those who die at the scene of the accident, is approximately 11,000 cases each year. The number of living patients in the United States as of December 2003 who have SCI, has been estimated as being approximately 243,000 persons. After initial injury, about half of those affect ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  6. Kidney Preservation for Transplantation

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Renal transplantation is the most effective and cost-efficient treatment for patients in end-stage kidney failure. However ischemia-reperfusion injury, associated with the retrieval, storage and transplantation of kidneys is a major immune-independent factor adversely affecting early graft function and graft viability. Marginal donors kidneys, are even more sus ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  7. LOW-COST AFFINITY SYSTEM FOR PREPARATION OF PLASMA/SERUM FOR BIOMARKER ANALYSIS

    SBC: APD LIFE SCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): We will develop a disposable, affinity-based capillary tube [AffiTip] that is capable of removing 99% of the interfering bulk protein from < 5 :L of undiluted plasma within 2 minutes for use prior to analysis for biomarkers [specific compounds that link mechanism of action and clinical effectiveness]. The product ultimately will be introduced at a sale price [p ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  8. Sphingosine Kinase Inhibitors as Anti-IBD Agents

    SBC: Apogee Biotechnology Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this program is to develop novel inhibitors of human sphingosine kinase (SK) that are effective as therapeutic agents. Because of its critical role in sphingolipid metabolism, we have focused on SK as an innovative molecular target for the development of new drugs for the treatment of Inflammatory Bowel Diseases (IBDs). Sphingolipids are being incre ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  9. Anti-Atherosclerosis Agents Targeting Sphingosine Kinase

    SBC: Apogee Biotechnology Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Principal Investigator/Program Director: French, Kevin J. Abstract: The long-term goal of this program is to develop inhibitors of human sphingosine kinase (SK) that are effective as therapeutic agents. Because of its critical role in sphingolipid metabolism, we have focused on SK as an innovative molecular target for the development of new drugs for the treatm ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Wearable Seizure Warning Device

    SBC: CHATTEN ASSOC., INC.            Topic: N/A

    DESCRIPTION (provided by applicant): In spite of advances in medical and surgical treatment, there are at any one time estimated to be some 350,000 individuals in this country whose seizures occur without warning and result in some combination of disordered thinking, impaired consciousness, or loss of motor control. Epileptologists and patients alike have long understood the magnitude of this prob ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government